Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hims & Hers HealthFRA:82W -4.17%82 EV-to-FCF is 132.38 as of Jul. 23, 2026, which is 283% above its 10-year median of 34.53. GuruFocus rates FRA:82W with a GF Score™ of 82/100 and a GF Value™ of €34.14 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 569 Drug Manufacturers companies, Hims & Hers Health ranks worse than 89.63% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Hims & Hers Health's Enterprise Value is €6,765 Mil.
Hims & Hers Health's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €51 Mil. Therefore, Hims & Hers Health's EV-to-FCF for today is 132.38.
The historical rank and industry rank for Hims & Hers Health's EV-to-FCF or its related term are showing as below:
FRA:82W'
s EV-to-FCF Range Over the Past 10 Years
Min: -379.11 Med: 34.53 Max: 164.4
Current: 127.72
During the past 7 years, the highest EV-to-FCF of Hims & Hers Health was 164.40. The lowest was -379.11. And the median was 34.53.
FRA:82W's EV-to-FCF is ranked worse than 89.63% of 569
companies
in the Drug Manufacturers industry
Industry Median: 21.07
vs FRA:82W: 127.72
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Hims & Hers Health (FRA:82W) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Hims & Hers Health's PE Ratio (TTM) for today is calculated as:
Hims & Hers Health's share price for today is €27.14.
Hims & Hers Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.080.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Hims & Hers Health EV-to-FCF Related Terms
Hims & Hers Health EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Hims & Hers Health's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Hims & Hers Health's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hims & Hers Health EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hims & Hers Health's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Hims & Hers Health's EV-to-FCF falls into.
Hims & Hers Health's current Enterprise Value is €6,765 Mil.
Hims & Hers Health's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €51 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hims & Hers Health (FRA:82W) has a EV-to-FCF of 132.38 as of Jul. 23, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Hims & Hers Health and its competitors. This is 283% above median its historical median of 34.53. According to the industry distribution chart, Hims & Hers Health ranks #510 out of 569 companies in the Drug Manufacturers industry, placing it in the top 89.6%.
Is Hims & Hers Health's EV-to-FCF too high?
Hims & Hers Health's current EV-to-FCF of 132.38 is 283% above median its 10-year median of 34.53. The Drug Manufacturers industry median EV-to-FCF is 21.07. Hims & Hers Health's value of 132.38 is 528.3% above this industry median. Based on the distribution chart, Hims & Hers Health ranks #510 out of 569 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Hims & Hers Health has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hims & Hers Health's EV-to-FCF compare to LNTH and LQDA?
According to the Drug Manufacturers industry distribution chart, Hims & Hers Health ranks #510 out of 569 companies for EV-to-FCF. This places Hims & Hers Health in the lower half of its industry. The industry median EV-to-FCF is 21.07. Hims & Hers Health's value of 132.38 is 528.3% above this benchmark. While the company's 10-year median is 34.53 vs. the industry median of 21.07, Hims & Hers Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 21.07, based on 569 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hims & Hers Health's current EV-to-FCF of 132.38 is 528.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Hims & Hers Health and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 21.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hims & Hers Health's current EV-to-FCF is 132.38, which is 283% above median its own 10-year median of 34.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hims & Hers Health stock overvalued right now?
Based on GuruFocus' analysis, Hims & Hers Health (FRA:82W) is currently considered Modestly Undervalued. The stock's GF Value™ is €34.14, compared to a current price of €27.14 — trading 20.5% below its estimated fair value. The current EV-to-FCF is 132.38, which is 283% above median its 10-year median of 34.53 and 528.3% above the Drug Manufacturers industry median of 21.07. Hims & Hers Health's overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Hims & Hers Health (FRA:82W), the current EV-to-FCF is 132.38 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hims & Hers Health (FRA:82W) Overvalued in 2026?
Based on GuruFocus' analysis, Hims & Hers Health stock appears to be undervalued.
The current stock price of €27.14 is trading 20.5% below its estimated GF Value™ of €34.14.
GuruFocus considers Hims & Hers Health to be Modestly Undervalued.
Key valuation signals for FRA:82W:
EV-to-FCF: 132.38 (283% above median its 10-year median of 34.53)
GF Value™: €34.14 vs. price of €27.14 (20.5% below fair value)
Industry Position: 528.3% above the Drug Manufacturers median (#510 of 569)
No single metric tells the full story. See the FRA:82W stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
82GF Score
Get the complete analysis for FRA:82W
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:82W has been successfully added to your 
